Nicolas Lanthier
Cliniques Universitaires Saint-Luc · 351 works · 6,679 citations · h-index 33
Top works
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
- Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
- Kupffer cell activation is a causal factor for hepatic insulin resistance
- SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule
- Global multi-stakeholder endorsement of the MAFLD definition
- Discovery of the gut microbial signature driving the efficacy of prebiotic intervention in obese patients
- Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high‐fat diet
- Occult HBV reactivation induced by ibrutinib treatment: a case report.
- Intramural Hematoma of the Esophagus
- Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial
- Autologous Bone Marrow Mononuclear Cell Transplantation in Patients with Decompensated Alcoholic Liver Disease: A Randomized Controlled Trial
- Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis
- Kupffer Cells Influence Parenchymal Invasion and Phenotypic Orientation, but Not the Proliferation, of Liver Progenitor Cells in a Murine Model of Liver Injury
- Brown adipose tissue: a potential target in the fight against obesity and the metabolic syndrome
- Infliximab in the treatment of posterior uveitis in Behçet's disease
- Hepatobiliary and Pancreatic: Nivolumab‐related cholangiopathy
- The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis
- Adipose tissues as endocrine target organs
- Liver progenitor cells and therapeutic potential of stem cells in human chronic liver diseases.